Evaxion A/S Files Form 6-K

Ticker: EVAX · Form: 6-K · Filed: 2025-08-27T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, foreign-private-issuer, sec-filing

TL;DR

Evaxion A/S filed a 6-K on 8/27/25, confirming its foreign private issuer status and Danish HQ.

AI Summary

Evaxion A/S, a biotechnology company, filed a Form 6-K on August 27, 2025. This filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive office is located in Hoersholm, Denmark.

Why It Matters

This filing provides routine disclosure for foreign private issuers, informing investors about the company's reporting status and location.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not contain material non-public information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of a foreign private issuer required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country or that it has filed or is required to file with a stock exchange on which its securities are traded.

What is Evaxion A/S's reporting status?

Evaxion A/S is a foreign private issuer and files its annual reports under cover of Form 20-F.

Where is Evaxion A/S's principal executive office located?

Evaxion A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

What is the filing date of this Form 6-K?

This Form 6-K was filed on August 27, 2025.

Does Evaxion A/S submit this Form 6-K in paper format?

The filing does not explicitly state if it is submitted in paper format, but it indicates the registrant files annual reports under Form 20-F, which is standard for foreign private issuers.

From the Filing

0001171843-25-005608.txt : 20250827 0001171843-25-005608.hdr.sgml : 20250827 20250827081511 ACCESSION NUMBER: 0001171843-25-005608 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250827 FILED AS OF DATE: 20250827 DATE AS OF CHANGE: 20250827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251259834 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_082725.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On August 27, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present at several conferences during the second half of 2025". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits Exhibit No.   Description       99.1   Evaxion to present at several conferences during the second half of 2025 SIGNATURES Pursuant to the requirements o

View on Read The Filing